Tiny implants take aim at prostate cancer: a smarter shot?

NCT ID NCT01902680

Completed Disease control Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a precise radiation implant (brachytherapy) for men with low-risk prostate cancer. Instead of treating the whole prostate, doctors placed radioactive seeds only in the tumor area. The goal was to see if this targeted approach could deliver the right radiation dose safely. Only 18 men took part, and the study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iodine-125 (I125) radioactive implant
What this could lead to: If successful, this could show that a targeted radiation implant can control low-risk prostate cancer with fewer side effects than whole-gland treatment.
What could go wrong: This is a very small, early-phase study with only 18 participants. It focuses on technical feasibility, not long-term cancer control or cure. The approach may not work for all patients or may miss cancer cells outside the targeted area.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALIZED PROSTATE CANCER

Contacts and locations

Locations

Institut Claudius REGAUD

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.